Mark Stewart Chambers

This inventor holds 44 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Genentech, Inc., Merck + Co., Inc.. Active years: 1993-2025.

USPTO Granted Patents = 44 (Patent Applications = 1)

% Patents Active = 70.5

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 14)

Average Co-Inventor Count = 4.5

ph-index = 13

Forward Citations = 518(Granted Patents)

Location History:

Hertfordshire, GB (1993)
Watford Harts, GB (1997)
Watford, GB (1993 - 2003)
St. Neots, GB (2013)
Puckeridge, GB (2001 - 2015)

Company Filing History:

24 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

patents

5. 1 out of 3

Calliditas Therapeutics Suisse Sa

patents

6. 1 out of 56

Chdi Foundation, Inc.

patents

7. 1 out of 20

Neumora Therapeutics, Inc.

patents

8. 1 out of 1

Soley Therapeutics, Inc.

patent

Years Active: 1993-2025

Loading Chart...

Areas of Expertise:

Huntington's Disease

NADPH Oxidase Inhibitors

LRRK2 Modulators

GABA Receptor Ligands

Cognition Enhancers

Tachykinin Receptor Antagonists

Benzodiazepine Derivatives

Alzheimer's Disease

Pyrazole Derivatives

Aminopyrimidine Derivatives

Triazoloquinazolines

Thienycyclohexanone Derivatives

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12465603 - Phthalazinone based modulators for the treatment of disease (2025-11-11),

2. 12281116 - HTT modulators for treating Huntington's disease (2025-04-21),

3. 12202816 - Compounds as NADPH oxidase inhibitors (2025-01-21),

4. 12152038 - Vasopressin receptor antagonists and products and methods related thereto (2024-11-26),

5. 9212173 - Pyrazole aminopyrimidine derivatives as LRRK2 modulators (2015-12-15),

6. 9145402 - Aminopyrimidine derivatives as LRRK2 modulators (2015-09-29),

7. 8815882 - Pyrazole aminopyrimidine derivatives as LRRK2 modulators (2014-08-26),

8. 8809331 - Aminopyrimidine derivatives as LRRK2 modulators (2014-08-19),

9. 8802674 - Aminopyrimidine derivatives as LRRK2 modulators (2014-08-12),

10. 8796296 - Aminopyrimidine derivatives as LRRK2 modulators (2014-08-05),

11. 8791130 - Aminopyrimidine derivatives as LRRK2 modulators (2014-07-29),

12. 8354420 - Aminopyrimidine derivatives as LRRK2 inhibitors (2013-01-15),

13. 7592456 - [object Object] (2009-09-22),

14. 7482457 - Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands (2009-01-27),

15. 7271191 - Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease (2007-09-18),

Hello! I'm glad to assist you with the article about inventor Mark Stewart Chambers.

Title: Innovator Spotlight: Mark Stewart Chambers - Pioneering Solutions for Parkinson's Disease

Introduction:

Mark Stewart Chambers, a talented inventor hailing from Puckeridge, GB, has made significant contributions in the field of pharmaceuticals and biotechnology. With an impressive portfolio of 40 patents, his innovative spirit shines through in his latest groundbreaking patents related to Parkinson's disease.

Latest Patents:

Chambers' recent patents include "Pyrazole aminopyrimidine derivatives as LRRK2 modulators" and "Aminopyrimidine derivatives as LRRK2 modulators." These patents focus on compounds that modulate the LRRK2 receptor, offering promising treatment approaches for diseases such as Parkinson's.

Career Highlights:

Having worked with renowned companies like Merck Sharp & Dohme Corporation (known as Merck) and Genentech, Inc., Chambers has honed his skills and expertise in pharmaceutical research and development. His innovative solutions have the potential to revolutionize the treatment of neurological disorders.

Collaborations:

Throughout his career, Chambers has collaborated with esteemed professionals in the industry, including Philip Jones and Charles Baker-Glenn. These collaborations have fostered a culture of innovation and knowledge sharing, leading to groundbreaking advancements in pharmaceutical science.

Conclusion:

Mark Stewart Chambers' dedication to developing novel treatments for Parkinson's disease exemplifies his passion for making a positive impact on global healthcare. With a keen focus on innovation and collaboration, Chambers continues to inspire the scientific community with his pioneering inventions.